These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 30469511)

  • 1. Aberrant Epigenetic Regulation in Head and Neck Cancer Due to Distinct EZH2 Overexpression and DNA Hypermethylation.
    Mochizuki D; Misawa Y; Kawasaki H; Imai A; Endo S; Mima M; Yamada S; Nakagawa T; Kanazawa T; Misawa K
    Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30469511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma.
    Cao W; Feng Z; Cui Z; Zhang C; Sun Z; Mao L; Chen W
    Cancer; 2012 Jun; 118(11):2858-71. PubMed ID: 21989926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation.
    Gannon OM; Merida de Long L; Endo-Munoz L; Hazar-Rethinam M; Saunders NA
    Clin Cancer Res; 2013 Jan; 19(2):428-41. PubMed ID: 23186778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of EZH2 inhibits epithelial‑mesenchymal transition in head and neck squamous cell carcinoma via regulating the STAT3/VEGFR2 axis.
    Zhao M; Hu X; Xu Y; Wu C; Chen J; Ren Y; Kong L; Sun S; Zhang L; Jin R; Zhou X
    Int J Oncol; 2019 Nov; 55(5):1165-1175. PubMed ID: 31545422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity.
    Chang JW; Gwak SY; Shim GA; Liu L; Lim YC; Kim JM; Jung MG; Koo BS
    Oral Oncol; 2016 Jan; 52():66-74. PubMed ID: 26604082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of Sal-like protein 4 in head and neck cancer: epigenetic effects and clinical correlations.
    Misawa K; Misawa Y; Mima M; Yamada S; Imai A; Mochizuki D; Nakagawa T; Kurokawa T; Endo S; Kawasaki H; Brenner JC; Mineta H
    Cell Oncol (Dordr); 2020 Aug; 43(4):631-641. PubMed ID: 32240499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. X-linked FHL1 as a novel therapeutic target for head and neck squamous cell carcinoma.
    Cao W; Liu J; Xia R; Lin L; Wang X; Xiao M; Zhang C; Li J; Ji T; Chen W
    Oncotarget; 2016 Mar; 7(12):14537-50. PubMed ID: 26908444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of EZH2 inhibitory drugs in human papillomavirus-positive and human papillomavirus-negative oropharyngeal squamous cell carcinomas.
    Lindsay CD; Kostiuk MA; Harris J; O'Connell DA; Seikaly H; Biron VL
    Clin Epigenetics; 2017; 9():95. PubMed ID: 28878842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting EZH2 regulates tumor growth and apoptosis through modulating mitochondria dependent cell-death pathway in HNSCC.
    Zhou X; Ren Y; Kong L; Cai G; Sun S; Song W; Wang Y; Jin R; Qi L; Mei M; Wang X; Kang C; Li M; Zhang L
    Oncotarget; 2015 Oct; 6(32):33720-32. PubMed ID: 26378043
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Sailer V; Holmes EE; Gevensleben H; Goltz D; Dröge F; Franzen A; Dietrich J; Kristiansen G; Bootz F; Schröck A; Dietrich D
    Clin Epigenetics; 2017; 9():12. PubMed ID: 28174607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2 overexpression in head and neck cancer is related to lymph node metastasis.
    Nienstedt JC; Schroeder C; Clauditz T; Simon R; Sauter G; Muenscher A; Blessmann M; Hanken H; Pflug C
    J Oral Pathol Med; 2018 Mar; 47(3):240-245. PubMed ID: 29285811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma.
    Misawa K; Misawa Y; Kondo H; Mochizuki D; Imai A; Fukushima H; Uehara T; Kanazawa T; Mineta H
    PLoS One; 2015; 10(3):e0118588. PubMed ID: 25734919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer.
    Misawa K; Mochizuki D; Imai A; Endo S; Mima M; Misawa Y; Kanazawa T; Carey TE; Mineta H
    Oncotarget; 2016 May; 7(18):26087-98. PubMed ID: 27027429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EZH2 Expression in Head-and-Neck Squamous Cell Cancer in Young Patients.
    Révész M; Oberna F; Slezák A; Tóth E; Ferenczi Ö; Kenessey I; Takácsi-Nagy Z
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant overexpression of EZH2 and H3K27me3 serves as poor prognostic biomarker for esophageal squamous cell carcinoma patients.
    Liu F; Gu L; Cao Y; Fan X; Zhang F; Sang M
    Biomarkers; 2016; 21(1):80-90. PubMed ID: 26631178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis.
    Misawa K; Mochizuki D; Endo S; Mima M; Misawa Y; Imai A; Shinmura K; Kanazawa T; Carey TE; Mineta H
    Mol Carcinog; 2017 Mar; 56(3):1107-1116. PubMed ID: 27685843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma.
    Bennett KL; Hackanson B; Smith LT; Morrison CD; Lang JC; Schuller DE; Weber F; Eng C; Plass C
    Cancer Res; 2007 May; 67(10):4657-64. PubMed ID: 17510391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer.
    Misawa Y; Misawa K; Kanazawa T; Uehara T; Endo S; Mochizuki D; Yamatodani T; Carey TE; Mineta H
    Cancer; 2014 Jan; 120(2):205-13. PubMed ID: 24122450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycomb repressive complex 2 and its core component EZH2: potential targeted therapeutic strategies for head and neck squamous cell carcinoma.
    Cheng Y; Song Z; Fang X; Tang Z
    Clin Epigenetics; 2024 Apr; 16(1):54. PubMed ID: 38600608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients.
    Pavón MA; Arroyo-Solera I; Téllez-Gabriel M; León X; Virós D; López M; Gallardo A; Céspedes MV; Casanova I; López-Pousa A; Mangues MA; Quer M; Barnadas A; Mangues R
    Oncotarget; 2015 Oct; 6(30):29016-33. PubMed ID: 26359694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.